Milestone Pharmaceuticals Inc
MIST
Company Profile
Business description
Milestone Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of cardiovascular medicines. Its approved product CARDAMYST (etripamil) nasal spray is available in the United States and is the self-administered treatment for use by patients anywhere, anytime an attack of PSVT occurs. It operates in single segment.
Contact
1111 Dr. Frederik-Phillips Boulevard
Suite 420
MontrealQCH4M 2X6
CANT: +1 514 336-0444
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
38
Stocks News & Analysis
stocks
Eli Lilly receives FDA approval to add another oral GLP-1 to market
Wide moat Eli Lilly receives FDA approval for obesity pill.
stocks
Our top ASX picks in every sector
These companies are our favourite choices for investors wanting to boost Aussie equity exposure.
stocks
Which of the 3 giant AI IPOs should you buy?
OpenAI, Anthropic, and Databricks are expected to go public this year at massive valuations.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,774.90 | 124.80 | -1.40% |
| CAC 40 | 7,908.82 | 72.45 | -0.91% |
| DAX 40 | 22,916.77 | 382.12 | -1.64% |
| Dow JONES (US) | 46,196.17 | 369.57 | -0.79% |
| FTSE 100 | 10,393.58 | 28.79 | 0.28% |
| HKSE | 25,116.53 | 177.50 | -0.70% |
| NASDAQ | 21,612.97 | 227.98 | -1.04% |
| Nikkei 225 | 52,463.27 | 1,276.41 | -2.38% |
| NZX 50 Index | 12,902.15 | 76.28 | 0.59% |
| S&P 500 | 6,527.28 | 48.04 | -0.73% |
| S&P/ASX 200 | 8,579.50 | 105.50 | -1.21% |
| SSE Composite Index | 3,919.29 | 29.27 | -0.74% |